Back to Search
Start Over
Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
- Source :
- Heliyon, Vol 5, Iss 7, Pp e02004-(2019), Heliyon
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy could be a candidate for treatment. Here, we immunohistochemically evaluated HER2 expression in 21 paraffin-embedded cTC tissues and scored the degree of expression based on intensity and positivity (score: 0–3+). Four samples (19%) scored 3+; 6 (29%), 2+; 7 (33%), 1+; and 4 (19%), 0. Therefore, 48% of the cTC tissues were HER2 positive (scored ≥2+). These data may lead to further evaluation of the role of HER2 in cTC as a mechanism of malignancy and a therapeutic target.
- Subjects :
- 0301 basic medicine
Pathology
medicine.medical_specialty
Veterinary medicine
Cancer research
Malignancy
Article
Thyroid cancer
Metastasis
Thyroid carcinoma
03 medical and health sciences
0302 clinical medicine
Medicine
Endocrine system
lcsh:Social sciences (General)
lcsh:Science (General)
skin and connective tissue diseases
neoplasms
Multidisciplinary
Her2 expression
business.industry
Thyroid
Canis familiaris
medicine.disease
030104 developmental biology
medicine.anatomical_structure
Oncology
Oncogene protein HER-2
Immunohistochemistry
lcsh:H1-99
business
030217 neurology & neurosurgery
lcsh:Q1-390
Subjects
Details
- ISSN :
- 24058440
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Heliyon
- Accession number :
- edsair.doi.dedup.....26e4b2012b66ff6a8a36a32bcaf53afd
- Full Text :
- https://doi.org/10.1016/j.heliyon.2019.e02004